GlassScriptPhysician profile
Ayoola Adekile
NPI 1659574135
$4,636.91
in general payments reported to CMS, 2019-2025
28 companies · $2,721 in 2025
The $2,721 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $35.94 · 2021: $70.70 · 2022: $696 · 2023: $398 · 2024: $400 · 2025: $2,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,100 · Food and Beverage: $1,278 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,100.00 |
| Food and Beverage | $1,277.57 |
| Education | $141.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $2,322.67 | 2023-2025 | Tarpeyo |
| Biomerieux INC | $442.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $211.83 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $210.53 | 2019-2024 | Lokelma, Farxiga, Flumist Quadrivalent |
| Veloxis Pharmaceuticals, INC. | $209.85 | 2019-2025 | Envarsus |
| Merck Sharp & Dohme LLC | $188.12 | 2025 | Prevymis |
| Alexion Pharmaceuticals, INC. | $157.49 | 2019-2024 | Soliris |
| Amgen INC. | $129.06 | 2019-2025 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $126.28 | 2021-2024 | Livtencity, Gattex |
| Vifor Pharma, INC. | $92.22 | 2019-2023 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $74.85 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $70.22 | 2023-2024 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.09 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $39.57 | 2019-2024 | Nulojix |
| Glaxosmithkline, LLC. | $39.06 | 2023-2025 | Benlysta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36.74 | 2024 | Jynarque |
| Ani Pharmaceuticals, INC. | $31.61 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $22.97 | 2025 | |
| Fresenius USA Marketing, INC. | $21.98 | 2024 | Velphoro |
| Vyera Pharmaceuticals, LLC | $19.65 | 2019 | |
| Aurinia Pharma U.S., INC. | $18.73 | 2023 | Lupkynis |
| Genentech, INC. | $18.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.41 | 2025 | |
| Horizon Therapeutics Plc | $17.02 | 2022 | |
| Abiomed | $16.30 | 2022 | |
| Lilly USA, LLC | $15.35 | 2024 | Jardiance |
| Boston Scientific Corporation | $14.17 | 2023 | |
| Ascensia Diabetes Care US INC. | $13.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayoola Adekile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.